Mineralys Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage produ...
Latest News
8 days ago · globenewswire.com
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from Launch-HTN baseline –
12 days ago · seekingalpha.com
Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise, restrictive payer policies, and step therapy barriers, limiting near-term market penetration. Peak sales for lorundrostat are modeled at ~$800 million, but the current valuation appears fair; I upgrade from 'Sell' to 'Hold' given the risk/reward balance.
12 days ago · marketbeat.com
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings CallMineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for Dec. 22, executives said on the company's third-quarter earnings call.
12 days ago · seekingalpha.com
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call TranscriptMineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
13 days ago · globenewswire.com
Mineralys Therapeutics to Participate in Upcoming Investor ConferencesRADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that members of senior management will be participating in fireside chats at three upcoming investor conferences.
19 days ago · globenewswire.com
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the third quarter ended September 30, 2026, after the financial markets close on Wednesday, November 4, 2026.
20 days ago · globenewswire.com
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
25 days ago · globenewswire.com
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD
28 days ago · globenewswire.com
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsRADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that Kristine Peterson and Lonnel Coats have been appointed to the Company's Board of Directors.
1 month ago · globenewswire.com
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MLYS